Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
M Joerger, J von Pawel, S Kraff, J R Fischer, W Eberhardt, T C Gauler, L Mueller, N Reinmuth, M Reck, M Kimmich, F Mayer, H-G Kopp, D M Behringer, Y-D Ko, R A Hilger, M Roessler, C Kloft, A Henrich, B Moritz, M C Miller, S J Salamone, U Jaehde, M Joerger, J von Pawel, S Kraff, J R Fischer, W Eberhardt, T C Gauler, L Mueller, N Reinmuth, M Reck, M Kimmich, F Mayer, H-G Kopp, D M Behringer, Y-D Ko, R A Hilger, M Roessler, C Kloft, A Henrich, B Moritz, M C Miller, S J Salamone, U Jaehde
Abstract
Background: Variable chemotherapy exposure may cause toxicity or lack of efficacy. This study was initiated to validate pharmacokinetically (PK)-guided paclitaxel dosing in patients with advanced non-small-cell lung cancer (NSCLC) to avoid supra- or subtherapeutic exposure.
Patients and methods: Patients with newly diagnosed, advanced NSCLC were randomly assigned to receive up to 6 cycles of 3-weekly carboplatin AUC 6 or cisplatin 80 mg/m(2) either with standard paclitaxel at 200 mg/m(2) (arm A) or PK-guided dosing of paclitaxel (arm B). In arm B, initial paclitaxel dose was adjusted to body surface area, age, sex, and subsequent doses were guided by neutropenia and previous-cycle paclitaxel exposure [time above a plasma concentration of 0.05 µM (Tc>0.05)] determined from a single blood sample on day 2. The primary end point was grade 4 neutropenia; secondary end points included neuropathy, radiological response, progression-free survival (PFS) and overall survival (OS).
Results: Among 365 patients randomly assigned, grade 4 neutropenia was similar in both arms (19% versus 16%; P = 0.10). Neuropathy grade ≥2 (38% versus 23%, P < 0.001) and grade ≥3 (9% versus 2%, P < 0.001) was significantly lower in arm B, independent of the platinum drug used. The median final paclitaxel dose was significantly lower in arm B (199 versus 150 mg/m(2), P < 0.001). Response rate was similar in arms A and B (31% versus 27%, P = 0.405), as was adjusted median PFS [5.5 versus 4.9 months, hazard ratio (HR) 1.16, 95% confidence interval (CI) 0.91-1.49, P = 0.228] and OS (10.1 versus 9.5 months, HR 1.05, 95% CI 0.81-1.37, P = 0.682).
Conclusion: PK-guided dosing of paclitaxel does not improve severe neutropenia, but reduces paclitaxel-associated neuropathy and thereby improves the benefit-risk profile in patients with advanced NSCLC.
Clinical trial information: NCT01326767 (https://ichgcp.net/clinical-trials-registry/NCT01326767).
Keywords: neuropathy; non-small-cell lung cancer; paclitaxel; pharmacokinetics; therapeutic drug monitoring.
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Source: PubMed